CSACI position statement: transition recommendations on existing epinephrine autoinjectors

Epinephrine is the first line treatment for anaphylaxis, an acute potentially life-threatening allergic reaction. It is typically administered intramuscularly in the anterolateral thigh at a dose of 0.01 mg/kg of 1:1000 (1 mg/ml) solution to a maximum initial dose of 0.5 mg. Currently in Canada, epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lucy Dong Xuan, Abrams, Elissa M., Lavine, Elana, Hildebrand, Kyla, Mack, Douglas Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670273/
https://www.ncbi.nlm.nih.gov/pubmed/34903280
http://dx.doi.org/10.1186/s13223-021-00634-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670273/
https://www.ncbi.nlm.nih.gov/pubmed/34903280
http://dx.doi.org/10.1186/s13223-021-00634-2

Ejemplares similares